Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin McKibbin

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Molecular Diagnosis & Therapy|June 7, 2023
Long-Read Nanopore Sequencing of RPGR ORF15 is Enhanced Following DNase I Treatment of MinION Flow CellsSamar Yahya, Christopher M Watson, Ian Carr, et al.
Eye (London, England)|February 21, 2025
Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2 mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7Swati Chandak, Sarega Gurudas, Raheeba Mohammed Pakeer, et al.
Translational Vision Science & Technology|August 22, 2020
Quantifying the Separation Between the Retinal Pigment Epithelium and Bruch's Membrane using Optical Coherence Tomography in Patients with Inherited Macular DegenerationKamron N Khan, Shyamanga Borooah, Leonardo Lando, et al.
Ophthalmology. Retina|August 17, 2019
Direct Ophthalmic Healthcare Resource Use among Patients with Geographic Atrophy in a Large Cohort from the United KingdomUsha Chakravarthy, Clare C Bailey, Peter H Scanlon, et al.
Eye (London, England)|May 12, 2025
Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6Swati Chandak, Sarega Gurudas, Raheeba Pakeer Muhammed, et al.
Ophthalmology|March 26, 2019
Loss-of-Function Mutations in the CFH Gene Affecting Alternatively Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular DrusenRachel L Taylor, James A Poulter, Susan M Downes, et al.
Ophthalmology. Retina|March 8, 2020
Progression from Early/Intermediate to Advanced Forms of Age-Related Macular Degeneration in a Large UK Cohort: Rates and Risk FactorsUsha Chakravarthy, Clare C Bailey, Peter H Scanlon, et al.
Molecular Vision|June 13, 2022
Novel <i>SIX6</i> mutations cause recessively inherited congenital cataract, microcornea, and corneal opacification with or without coloboma and microphthalmiaEvangelia S Panagiotou, Narcis Fernandez-Fuentes, Layal Abi Farraj, et al.
Ophthalmology|January 26, 2018
Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular DegenerationUsha Chakravarthy, Clare C Bailey, Robert L Johnston, et al.
Eye (London, England)|May 6, 2024
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5Sridevi Thottarath, Sarega Gurudas, Swati Chandak, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Molecular Diagnosis & Therapy|June 7, 2023
Long-Read Nanopore Sequencing of RPGR ORF15 is Enhanced Following DNase I Treatment of MinION Flow CellsSamar Yahya, Christopher M Watson, Ian Carr, et al.
Eye (London, England)|February 21, 2025
Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2 mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7Swati Chandak, Sarega Gurudas, Raheeba Mohammed Pakeer, et al.
Translational Vision Science & Technology|August 22, 2020
Quantifying the Separation Between the Retinal Pigment Epithelium and Bruch's Membrane using Optical Coherence Tomography in Patients with Inherited Macular DegenerationKamron N Khan, Shyamanga Borooah, Leonardo Lando, et al.
Ophthalmology. Retina|August 17, 2019
Direct Ophthalmic Healthcare Resource Use among Patients with Geographic Atrophy in a Large Cohort from the United KingdomUsha Chakravarthy, Clare C Bailey, Peter H Scanlon, et al.
Eye (London, England)|May 12, 2025
Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6Swati Chandak, Sarega Gurudas, Raheeba Pakeer Muhammed, et al.
Ophthalmology|March 26, 2019
Loss-of-Function Mutations in the CFH Gene Affecting Alternatively Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular DrusenRachel L Taylor, James A Poulter, Susan M Downes, et al.
Ophthalmology. Retina|March 8, 2020
Progression from Early/Intermediate to Advanced Forms of Age-Related Macular Degeneration in a Large UK Cohort: Rates and Risk FactorsUsha Chakravarthy, Clare C Bailey, Peter H Scanlon, et al.
Molecular Vision|June 13, 2022
Novel <i>SIX6</i> mutations cause recessively inherited congenital cataract, microcornea, and corneal opacification with or without coloboma and microphthalmiaEvangelia S Panagiotou, Narcis Fernandez-Fuentes, Layal Abi Farraj, et al.
Ophthalmology|January 26, 2018
Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular DegenerationUsha Chakravarthy, Clare C Bailey, Robert L Johnston, et al.
Eye (London, England)|May 6, 2024
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5Sridevi Thottarath, Sarega Gurudas, Swati Chandak, et al.
Pageof 11